BCRX — BioCryst Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $2.05bn
- $2.52bn
- $874.84m
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026
BioCryst Pharmaceuticals Q2 revenue rises, lifts 2026 revenue guidance
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
Brief: Biocryst Presents New Clinical Data And Real-World Evidence Demonstrating Impact Of Hae Portfolio At The 2026 European Academy Of Allergy And Clinical Immunology Annual Meeting
U.S. STOCKS ON THE MOVE-Instacart, New York Times, Novavax
U.S. STOCKS ON THE MOVE-DaVita, Knight-Swift, Madrigal Pharma
U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber
BioCryst falls on surprise quarterly loss
BioCryst Q1 ORLADEYO revenue rises 11%, net loss widens
BioCryst 2025 revenue rises 94% on ORLADEYO sales
BioCryst rises on US FDA approval for oral formulation of rare disease drug
NASDAQ RESUMED AT 07:20 AM
FDA approves BioCryst's oral pellet formulation of rare disease drug for young children (updated)
FDA expands approval of BioCryst's rare disease drug for use in young children
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:41 AM
Brief: Biocryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)